PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Overview of cancer immunotherapies • Epidemiology • Spending on cancer • Cost of cancer treatment • Reimbursement policies • Economic burden of cancer • Orphan drug designation and regulatory approvals PART 06: Pipeline portfolio • Anticipated number of products with single and multi-indications by 2020 PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by type • Cancer monoclonal antibodies • Clinical trials of cancer monoclonal antibodies • Immune checkpoint inhibitors • Cancer vaccines • Non-specific immunotherapies • Global cancer monoclonal antibodies market • Global cancer vaccines market • Global immune checkpoint inhibitors market • Global non-specific immunotherapies market PART 09: Geographical segmentation • Global cancer immunotherapies market by geography 2015-2020 • Cancer immunotherapies market in Americas • Cancer immunotherapies market in EMEA • Cancer immunotherapies market in APAC PART 10: Market drivers • Increase in prevalence of cancers • Increase in demand for cancer monoclonal antibodies • Patient assistance programs • Promising pipeline PART 11: Impact of drivers PART 12: Market challenges • Patent expiry of top-selling drugs • Poor diagnosis and screening • High developmental costs • Risk of side-effects • Stringent regulations PART 13: Impact of drivers and challenges PART 14: Market trends • Increase in cancer awareness • Emergence of targeted and combination therapies • Emergence of biosimilars • Strategic alliances PART 15: Vendor landscape • Competitive scenario • Market share analysis 2015 • Amgen • Bristol-Myers Squibb • F. Hoffmann-La Roche • GlaxoSmithKline • Merck • Takeda Pharmaceuticals1 • Other prominent vendors PART 16: Appendix • List of abbreviations PART 17: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Cancer immunotherapies in global cancer drugs market Exhibit 03: Global incidence of cancer by type 2015 Exhibit 04: Global mortality by cancer type 2015 Exhibit 05: Estimated numbers of male and female cancer survivors by age in US 2014 Exhibit 06: Spending on cancer by distribution channels 2013 Exhibit 07: Annual treatment cost per patient for cancer immunotherapies 2014 Exhibit 08: Average cost of surgeries associated with cancer ($ millions) 2014 Exhibit 09: National reimbursement of cancer drugs by countries 2014 Exhibit 10: US FDA Orphan drug designations and approvals for cancer immunotherapies Exhibit 11: EU orphan drug designations and approvals for cancer immunotherapies Exhibit 12: Key events in cancer immunotherapies, discovery, and approvals Exhibit 13: Timeline of some cancer immunotherapies Exhibit 14: Phase III pipeline molecules for global cancer monoclonal antibodies market Exhibit 15: Phase II pipeline molecules for global cancer monoclonal antibodies market Exhibit 16: Phase I pipeline molecules for global cancer monoclonal antibodies market Exhibit 17: Pipeline molecules for global immune checkpoint inhibitors market Exhibit 18: Phase III pipeline molecules for global cancer vaccines market Exhibit 19: Near-launch immuno-oncology pipeline assets Exhibit 20: Global cancer immunotherapies market 2015-2020 ($ billions) Exhibit 21: Factors influencing global cancer immunotherapies market Exhibit 22: Five forces analysis Exhibit 23: Global cancer immunotherapies market by type 2015 Exhibit 24: Timeline for approvals of cancer monoclonal antibodies by US FDA Exhibit 25: Clinical trials of cancer monoclonal antibodies by development phase Exhibit 26: Status of clinical trials of cancer monoclonal antibodies Exhibit 27: Global cancer immunotherapies market by type of cancer immunotherapies 2015 Exhibit 28: Global cancer immunotherapies market by type of cancer immunotherapies 2015-2020 ($ billions) Exhibit 29: Global cancer monoclonal antibodies market 2015-2020 ($ billions) Exhibit 30: Key drivers and challenges of global cancer monoclonal antibodies market Exhibit 31: Global cancer vaccines market 2015-2020 ($ billions) Exhibit 32: Global cancer vaccines market by application 2015 Exhibit 33: Key drivers and challenges of global cancer vaccines market Exhibit 34: Global immune checkpoint inhibitors market 2015-2020 ($ billions) Exhibit 35: Key drivers and challenges for global immune checkpoint inhibitors market Exhibit 36: Global non-specific immunotherapies market 2015-2020 ($ billions) Exhibit 37: Global cancer immunotherapies market by geography 2015 Exhibit 38: Global cancer immunotherapies market revenue by geography 2015-2020 ($ billions) Exhibit 39: Cancer immunotherapies market in Americas 2015-2020 ($ billions) Exhibit 40: Cancer immunotherapies market in EMEA 2015-2020 ($ billions) Exhibit 41: Cancer immunotherapies market in APAC 2015-2020 ($ billions) Exhibit 42: Global incidence of cancer 2015 and 2020 in millions Exhibit 43: Impact of drivers Exhibit 44: Patent expiries of major cancer monoclonal antibodies by 2020 Exhibit 45: Impact of drivers and challenges Exhibit 46: Expected combination regimen launches in oncology Exhibit 47: Top cancer immunotherapies based on sales 2014 ($ billions) Exhibit 48: YoY Sales comparison of top drugs 2011-2014 ($ billions) Exhibit 49: Cancer immunotherapy companies by origin country Exhibit 50: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2011-2014 ($ millions) Exhibit 51: Amgen: YoY growth and revenue generated from net product sales of Prolia 2011-2014 ($ millions) Exhibit 52: Amgen: YoY growth and revenue generated from net product sales of Vectibix worldwide excluding Japan 2011-2014 ($ millions) Exhibit 53: Amgen: YoY growth and revenue of Vectibix in US 2012-2014 ($ millions) Exhibit 54: Amgen: YoY growth and revenue of Vectibix in ROW 2012-2014 ($ millions) Exhibit 55: Amgen: Key takeaways Exhibit 56: Bristol-Myers Squibb: Segmentation by revenue 2014 Exhibit 57: Bristol-Myers Squibb: Revenue of oncology products by category 2014 Exhibit 58: Bristol-Myers Squibb: YoY growth and revenue generated from net product sales of Yervoy 2011-2014 ($ millions) Exhibit 59: Bristol-Myers Squibb: YoY growth and revenue of Erbitux in US, Canada, and Japan 2010-2014 ($ millions) Exhibit 60: Bristol-Myers Squibb: Key takeaways Exhibit 61: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of MabThera/Rituxan 2011-2014 ($ billions) Exhibit 62: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2011-2014 ($ billions) Exhibit 63: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2011-2014 ($ billions) Exhibit 64: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in US 2013-2014 ($ billions) Exhibit 65: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in EU 2013-2014 ($ billions) Exhibit 66: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in Japan 2013-2014 ($ millions) Exhibit 67: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2012-2014 ($ millions) Exhibit 68: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2014 ($ millions) Exhibit 69: F. Hoffmann-La Roche: Key takeaways Exhibit 70: GlaxoSmithKline: YOY growth and revenue of Arzerra 2012-2014 ($ millions)3 Exhibit 71: GlaxoSmithKline: YOY growth and revenue of Cervarix 2012-2014 ($ millions)3 Exhibit 72: GlaxoSmithKline: Key takeaways Exhibit 73: Merck: YoY growth and revenue of Gardasil 2012-2014 ($ billions)6 Exhibit 74: Merck: YoY growth and revenue generated from net product sales of Erbitux, excluding US, Canada, and Japan 2011-2014 ($ billions Exhibit 75: Merck: YOY growth and revenue of Erbitux in Europe 2012-2014 ($ millions) Exhibit 76: Merck: YOY growth and revenue of Erbitux in emerging markets 2012-2014 ($ millions) Exhibit 77: Merck: YOY growth and revenue of Erbitux in ROW 2012-2014 ($ millions) Exhibit 78: Merck: Region-wise revenues of Erbitux 2012-2014 ($ millions) Exhibit 79: Merck: Key takeaways Exhibit 80: Takeda Pharmaceuticals: YoY growth and revenue generated from net product sales of Adcetris ($ millions) Exhibit 81: Takeda Pharmaceuticals: YoY growth and revenue of Vectibix in Japan ($ millions) Exhibit 82: Takeda Pharmaceuticals: Key takeaways

Amgen Inc., Bristol-Myers Squibb, F. Hoffman-La Roche, GlaxoSmithKline Plc, Merck Inc., Takeda Pharmaceuticals, AbbVie, ADC Therapeutics, Agensys, Astellas, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, Boehringer-Ingelheim, Celgene, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed, Pfizer, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, TG Therapeutics, XBiotech.